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        Asthma and chronic obstructive pulmonary dis-
ease (COPD) are infl  ammatory airway diseases 
that are characterized by diff  erent patterns of air-
way remodeling (  1  ). Nevertheless, the decrease 
in lung function that characterizes both diseases 
is associated with an increased mass of bronchial 
smooth muscle (BSM) (  2, 3  ), which is likely to 
be the most important abnormality responsible 
for the airway narrowing observed in response 
to bronchoconstricting stimuli (  4  ). The mecha-
nisms underlying such remodeling of smooth 
muscle remain largely unknown. On the one 
hand, in smooth muscle from asthmatic patients, 
excessive in vitro proliferation of BSM cells has 
been demonstrated (  5  –  7  ). In addition, decreased 
apoptosis of BSM cells has also been demon-
strated, although this was in a rat model of ex-
perimental asthma (  7  ). On the other hand, in 
COPD, smooth muscle remodeling appears lim-
ited to airways distal to the fourth generation 
(  3, 8  ). Although an increase in TGF-     1 pro-
duction by BSM cells has been proposed, such 
localization and the complete mechanism remain 
unexplained (  9  ). Whatever its cause, BSM re-
modeling is poorly sensitive to current therapeu-
tics in both asthma and COPD. 
  Mitochondria play a major role in both cell 
proliferation and apoptosis (  10, 11  ). In cancer, 
for instance, targeting of mitochondrial function 
and mitochondrial antiapoptotic protein bcl-2 has 
been used to either suppress the proliferation of 
tumor cells (  10  ) or induce cell apoptosis in solid 
tu  mors (  12  ). Mitochondria are also involved 
in other diseases, such as neuron-degenerative 
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  Asthma and chronic obstructive pulmonary disease (COPD) are characterized by different 
patterns of airway remodeling, which all include an increased mass of bronchial smooth 
muscle (BSM). A remaining major question concerns the mechanisms underlying such a 
remodeling of BSM. Because mitochondria play a major role in both cell proliferation and 
apoptosis, we hypothesized that mitochondrial activation in BSM could play a role in this 
remodeling. We describe that both the mitochondrial mass and oxygen consumption were 
higher in the BSM from asthmatic subjects than in that from both COPD and controls. This 
feature, which is specifi  c to asthma, was related to an enhanced mitochondrial biogenesis 
through up-regulation of peroxisome proliferator-activated receptor      coactivator (PGC)  –
  1    , nuclear respiratory factor-1, and mitochondrial transcription factor A. The priming 
event of such activation was an alteration in BSM calcium homeostasis. BSM cell apoptosis 
was not different in the three groups of subjects. Asthmatic BSM was, however, character-
ized by increased cell growth and proliferation. Both characteristics were completely abro-
gated in mitochondria-defi  cient asthmatic BSM cells. Conversely, in both COPD and control 
BSM cells, induction of mitochondrial biogenesis reproduced these characteristics. Thus, 
BSM in asthmatic patients is characterized by an altered calcium homeostasis that in-
creases mitochondrial biogenesis, which, in turn, enhances cell proliferation, leading to 
airway remodeling. 3174 SMOOTH MUSCLE MITOCHONDRIAL BIOGENESIS IN ASTHMA | Trian et al.
and 18   ±   2.8 yr, respectively. Of the 19 control subjects who 
received no treatment, 8 of them were lifelong nonsmokers, 
whereas 11 were former smokers. 
diseases (  11  ). However, their role in asthma or COPD remains 
to be investigated. We hypothesized that mitochondrial 
activation in BSM from asthmatic or COPD patients could 
contribute to smooth muscle remodeling. To investigate this 
hypothesis, we have compared mitochondrial mass, activity, 
and biogenesis in BSM obtained from asthmatics, COPD 
patients, and normal controls. We describe that both the 
mitochondrial mass and oxygen consumption were higher 
in the BSM from asthmatic subjects than in that from both 
COPD and controls. This feature, which is specifi  c to asthma, 
is related to an enhanced mitochondrial biogenesis as a conse-
quence of an increase in extracellular calcium infl  ux upon ac-
tivation of asthmatic BSM cells. We also demonstrate a 
specifi  c mitochondria-dependent pathway for asthmatic BSM 
cell proliferation. Targeting such a pathway may thus rep-
resent a new approach for the treatment of airway remodel-
ing in asthma. 
    RESULTS   
  Clinical populations 
  The clinical characteristics of all subjects are shown in   Table I  .  
All of the 14 severe persistent asthmatics were lifelong non-
smokers and received stable treatments, including oral or 
inhaled corticosteroids and      2 agonists. 10 of them were atopic. 
The 17 moderate to severe COPD patients were either current 
or former smokers, and 9 of them received stable treatments, 
including oral or inhaled corticosteroids and/or      2 agonists. 
None of the asthmatic or COPD patients experienced a 
recent (  <  3 mo) exacerbation of the disease. The mean duration 
of the disease in asthmatic and COPD patients was 26   ±   4.6 
    Table I.        Clinical and functional characteristics of subjects 
Characteristic Patients with asthma Patients with COPD Controls
No. of patients 14 17 19
Age (yr) 42.3   ±   5.7 59.8   ±   3.0 60.4   ±   2.5
BMI (kg/m  2  ) 26.9   ±   1.1 24.0   ±   0.9 27.4   ±   1.1
Smoking history
     Pack years 0   ±   0 46.3   ±   4.8 19.5   ±   5.7
     Current (no. of patients) 0 8 0
     Former (no. of patients) 0 9 11
          Years since quitting - 11.4   ±   4.8 13.1   ±   3.8
Treatments
     LABA (no. of patients) 11 6 0
     ICS (no. of patients) 10 5 0
     OCS (no. of patients) 6 3 0
FEV  1 
     Liters 2.2   ±   0.2 1.8   ±   0.1 2.9   ±   0.1
     Percentage of predicted value 83.1   ±   6.3 60.2   ±   2.5 101.7   ±   3.2
FEV  1  : FVC ratio (% of FVC) 71.9   ±   3.7 56.3   ±   2.2 81.8   ±   1.7
FEF 25-75
     Liters sec     1 1.9   ±   0.3 0.9   ±   0.1 2.9   ±   0.1
     Percentage of predicted value 54.6   ±   7.8 28.6   ±   3.1 90.2   ±   4.0
Data are the mean   ±   the SEM. BMI, body mass index; LABA, long-acting      2 agonist; ICS, inhaled corticosteroid; OCS, oral corticosteroid; FEV  1  , forced expiratory volume in one 
second; FVC, forced vital capacity; FEF 25-75, forced expiratory fl  ow between 25 and 75% of FVC.
    Figure 1.     BSM remodeling in both asthma and COPD.   Representative 
optic microscopic images from bronchial sections stained with HES were 
obtained from an asthmatic (A), a COPD (B), or a control subject (C) 
and observed at 200  ×   magnifi  cation. Smooth muscles were visualized 
(SM). Bars, 50   μ  m. (D) The normalized smooth muscle area was assessed 
from microscopic images. Bronchial specimens were obtained from asth-
matic (black column;   n   = 10), COPD (gray column;   n   = 7), and control 
subjects (white column;   n   = 6). Data are the mean   ±   the SEM. *, P   <   0.05 
between populations using ANOVA with the use of Bonferroni  ’  s test.     JEM VOL. 204, December 24, 2007 
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.20070956/DC1; P = 0.02). There was a signifi  cant increase 
in the mitochondrial density in asthmatic BSM cells both 
ex vivo (  Fig. 2 E  ; P = 0.01) and in vitro (Fig. S1 E; P = 0.01) 
as compared with both COPD and controls. Based on elec-
tronic microscopy, the mitochondrial density has been shown 
to refl  ect the mitochondrial activity (  13, 14  ). To assess the 
smooth muscle specifi  city of these results, we also analyzed 
ultrastructural mitochondrial parameters in other cell types 
from the same bronchial specimens. There was no diff  erence 
between the three groups, in terms of both number (P = 0.35 
and P = 0.89) and density of mitochondria (P = 0.47 and P = 
0.87) in endothelial and epithelial cells, respectively (unpub-
lished data). The increased mass of asthmatic BSM mitochon-
dria was further confi  rmed, in vitro, by an increase in the porin 
content compared with that of both COPD and controls 
(  Fig. 2 F  ; P = 0.001). We also found within the asthmatic 
population that both duration of the disease and forced expi-
ratory volume in one second (FEV  1  )/ forced vital capacity 
  Mitochondrial mass and activity are increased only 
in the BSM of asthmatics 
  A morphological analysis of BSM was performed in the three 
groups of subjects (  Fig. 1, A  –  C  ).   BSM mass was increased in 
both asthmatic and COPD patients as compared with controls 
(  Fig. 1 D  ; P = 0.01). Ultrastructure of BSM mitochondria 
was then compared in asthma and COPD to control subjects 
(  Fig. 2, A-C  ).   The number of mitochondrial sections was 
higher in the BSM of asthmatics than in that of both COPD 
and controls (  Fig. 2 D  ; P   <   0.001). The mean area per section 
was, however, unchanged (0.1   ±   0.007, 0.1   ±   0.016, and 0.1   ±   
0.009   μ  m  2   for asthmatics, COPD, and controls, respectively; 
analysis of variance [ANOVA] P = 0.87). Collectively, these 
results favor the hypothesis that the increase in mitochondrial 
mass in the BSM of asthmatics is related to an increase in 
number rather than in individual size. Similar results were 
obtained with cultured growth-arrested BSM cells (Fig. S1, 
A  –  D, available at http://www.jem.org/cgi/content/full/jem
    Figure 2.     Increased mitochondrial mass and activity in asthmatic BSM.   Representative electronic microscopic images from bronchial sections 
were obtained from an asthmatic (A), a COPD (B), or a control subject (C) and observed at 26,000  ×   magnifi  cation. Some smooth muscle mitochondria 
were visualized (arrows). Bars, 0.2   μ  m. The number (D) and the density (E) of mitochondria were assessed from electronic microscopic images (  n   = 4 for 
each population). Mitochondrial mass was assessed by the porin content using Western blot (F;   n   = 8 for asthmatics,   n   = 5 for COPD, and   n   = 7 for con-
trols). Endogenous cellular oxygen consumption was evaluated by oxygraphy (G;   n   = 5 for asthmatics,   n   = 4 for COPD, and   n   = 4 for controls). BSM cells 
(BSMC) were obtained from asthmatic (black columns), COPD (gray columns), and control subjects (white columns). Data are the mean   ±   the SEM. 
*, P   <   0.05 between populations using ANOVA with the use of Bonferroni  ’  s test.     3176 SMOOTH MUSCLE MITOCHONDRIAL BIOGENESIS IN ASTHMA | Trian et al.
D and E  ). Upstream mechanisms that would explain such an 
increased mitochondrial biogenesis were then examined. The 
two transcription factors nuclear respiratory factor-1 (NRF-1) 
and peroxisome proliferator  –  activated receptor       coactivator  –
  1      (PGC-1     ) were both elevated in asthmatic BSM cells at 
both the protein and the transcription levels (  Fig. 3, D and E  ). 
Among the various factors that could activate PGC-1     , we 
observed that the calcium/calmodulin-dependent protein 
kinase IV (CaMK-IV) was phosphorylated and thus activated in 
asthmatic BSM cells compared with controls and COPD (  Fig. 
4 A  ).   We thus investigated whether calcium homeostasis was 
deregulated in asthmatic BSM cells using microspectrofl  uo-
rimetry. The resting calcium concentration was consistent 
in asthmatic (125   ±   8 nM), COPD (127   ±   7 nM), or control 
BSM cells (133   ±   4 nM; P = 0.60). However, the calcium re-
sponse to acetylcholine was signifi  cantly altered in asthmatic 
BSM cells (  Fig. 4, B  –  D  ). Whereas the amplitude of the calcium 
rise was unchanged (275   ±   20, 284   ±   43, and 272   ±   27 nM in 
asthmatics, COPD, and controls, respectively; P = 0.95), the 
area under the curve was signifi  cantly increased in asthmatic 
BSM cells (  Fig. 4 E  ). A similar result was obtained in asthmatic 
BSM cells stimulated with histamine, confi  rming that it was 
not agonist-specifi  c (Fig. S3, A  –  D, available at http://www
.jem.org/cgi/content/full/jem.20070956/DC1). An enhanced 
calcium infl  ux in asthmatic BSM cells accounts for this result, 
as both removal of extracellular calcium using EGTA and 
blockade of calcium channels using methoxyverapamil (D600) 
abolished such abnormal calcium responses in asthmatic BSM 
cells (  Fig. 4 E   and Fig. S3 D). Blockade of calcium infl  ux using 
D600 also inhibited the activation of CaMK-IV (  Fig. 4 A  ) and 
the subsequent activation of mitochondrial biogenesis through 
(FVC) ratio were correlated with the porin content (r = 0.77, 
P = 0.03 and r =      0.84, P = 0.01, respectively), whereas no 
correlation was found within the COPD or the control pop-
ulation. Similarly, the oxygen consumption of asthmatic BSM 
cells was specifi  cally enhanced compared with COPD or control 
BSM cells (  Fig. 2 G  ; P = 0.01). Such an increase in the mito-
chondrial respiratory rate was not associated with diff  erences 
in the coupling degree, as demonstrated by the effects of 
inhibitors of the phosphorylation system. Similarly, oxygen 
consumption of COPD and control BSM, although lower, also 
refl   ected coupled mitochondrial respiration (Fig. S2; P   <   
0.04, paired   t   tests). These inhibitors decreased the mito-
chondrial respiration of asthmatics, COPD, and controls by 
18.6, 21.2, and 24.7%, respectively, whereas cyanide com-
pletely inhibited oxygen consumption of all BSM cells. The 
increased mitochondrial respiration in asthma thus appears to 
result from the increased organelle content and subsequent 
enhancement in the overall oxidative capacity in BSM. 
  Mitochondrial biogenesis is increased in asthmatic BSM 
cells through a calcium-dependent pathway 
  We next analyzed the mitochondrial network by confocal 
microscopy (  Fig. 3, A  –  C  ).   Surprisingly, asthmatic BSM cells 
presented a typical aspect of intense mitochondrial biogenesis, 
as shown by the presence of several budding areas with intense 
dots, and a wider network with increased ramifi  cation (  Fig. 3 A  ). 
Because the mitochondrial transcription factor A (mtTFA) is 
the main factor involved in mitochondrial biogenesis, we 
measured its protein content and transcription level in the 
three groups of BSM. As compared with both controls and 
COPD, mtTFA was increased in asthmatic BSM cells (  Fig. 3, 
    Figure 3.     Increased mitochondrial biogenesis in asthmatic BSM.   Representative confocal images of the mitochondrial network after three dimen-
sional reconstruction were obtained from asthmatic (A), COPD (B), or control (C) BSM cells. Bars, 10   μ  m. mtTFA, NRF-1, and PGC-1      levels were assessed 
by both Western blot (D) and quantitative RT-PCR (E). BSM cells were obtained from asthmatic (black columns;   n   = 6), COPD (gray columns;   n   = 7), and 
control subjects (white columns;   n   = 6). Data are the mean   ±   the SEM. *, P   <   0.05 between populations using ANOVA with the use of Bonferroni  ’  s test.     JEM VOL. 204, December 24, 2007 
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of anaerobic glycolysis. For this purpose, BSM cell proliferation 
curves were plotted in the three groups of subjects using 
either glucose or galactose in the culture medium (  Fig. 6, 
A and B  ).  In the presence of glucose, which allows ATP to be 
produced by both aerobic and anaerobic glycolysis, asthmatic 
BSM cell growth was signifi  cantly increased compared with 
that of COPD and control subjects (  Fig. 6 A  ; P = 0.02), with 
a concomitant decrease in the doubling time (  Fig. 6 C  ; P = 
0.02). When galactose, which only allows cells to produce 
ATP by mitochondrial oxidative phosphorylations, was substi-
tuted for glucose, the doubling time of the cell growth from 
both COPD (P = 0.02) and control subjects (P = 0.02) sig-
nifi  cantly increased, whereas that of asthmatic cells remained 
constant (  Fig. 6, B and C  ). Because an increase in cell growth 
can be related to a decreased apoptosis and/or an increased 
proliferation, we analyzed Annexin V binding and BrdU in-
corporation, respectively. Taking into account the percent-
age of Annexin V  –  positive cells, spontaneous apoptosis was 
not altered in asthmatic BSM cells as compared with that of 
COPD and controls (Fig. S4, available at http://www.jem
.org/cgi/content/full/jem.20070956/DC1). However, BrdU 
incorporation increased in BSM cells from asthmatics as com-
pared with that in both COPD and controls in the presence 
of glucose (  Fig. 6 D  ; P = 0.01). Incubation for 11 d in the 
absence of glucose signifi  cantly inhibited BrdU incorporation 
in BSM cells from controls (P = 0.02) and COPD patients 
(P = 0.02), but not in that from asthmatics (  Fig. 6 D  ; P = 0.99). 
Collectively, these results demonstrate that the proliferation 
of asthmatic BSM cells mainly uses mitochondrial-dependent 
PGC-1     , NRF-1, and mtTFA (  Fig. 5, A  –  C  ), leading to the 
increase in the mitochondrial mass as assessed by the porin 
content (  Fig. 5 D  ).  Thus, these results indicate that an enhanced 
extracellular calcium infl  ux, specifi  c to asthmatic BSM cells, is 
the initial priming event leading to an increased mitochondrial 
biogenesis and mass. 
  Only asthmatic BSM cell proliferation is mitochondria 
dependent 
  To further assess the specifi  c role of mitochondria in asth-
matic BSM proliferation contributing to airway remodeling, 
we next compared BSM cell growth in the presence or absence 
    Figure 4.     Altered cell calcium homeostasis in asthmatic BSM.  
(A)     Phosphorylated CaMK-IV (P-CaMK-IV) levels were assessed by Western 
blot. Representative intracellular calcium responses after stimulation for 
30 s by 10      5   M acetylcholine (ACh) are presented in BSM cells from asth-
matic (B), COPD (C), or control subjects (D). As a reference, response from 
the control cell (D) is presented as a gray line (B and C). The area under 
the curve was assessed from the calcium response (E). BSM cells were 
analyzed in the absence (-) or presence (+) of 2 mM extracellular Ca  2 +   or 
1   μ  M methoxyverapamil (D600). Cells were obtained from asthmatic 
(black columns;   n   = 5), COPD (gray columns;   n   = 4), and control subjects 
(white columns;   n   = 4). Data are the mean   ±   the SEM. *, P   <   0.05 between 
populations within an experimental condition using ANOVA with the use 
of Bonferroni  ’  s test.   †  , P   <   0.05 between experimental conditions versus 2 
mM Ca  2+   without D600 within a population using paired Student’s   t   tests.   
    Figure 5.     Effect of methoxyverapamil (D600) on mitochondrial 
biogenesis and content.   PGC-1     (A), NRF-1 (B), mtTFA (C), and porin (D) 
levels were assessed by Western blot in BSM cells cultured in the absence 
(-) or presence (+) of 1   μ  M D600 for 48 h. Cells were obtained from asth-
matic (black columns;   n   = 5), COPD (gray columns;   n   = 4), and control 
subjects (white columns;   n   = 4). Data are the mean   ±   the SEM. *, P   <   0.05 
between populations within an experimental condition using ANOVA with 
the use of Bonferroni  ’  s test.   †  , P   <   0.05 between the absence and the 
presence of D600 within a population using paired Student’s   t   tests.   3178 SMOOTH MUSCLE MITOCHONDRIAL BIOGENESIS IN ASTHMA | Trian et al.
porin in the three groups of subjects (  Fig. 7  ).    Fig. 6 C   dem-
onstrates that ethidium bromide signifi  cantly increased the 
doubling time of asthmatic BSM cells (P   <   0.001), but did 
not change that of both COPD (P = 0.15) and control cells 
(P = 0.09). Similarly, proliferation of mitochondria-defi  cient 
asthmatic BSM cells decreased (P   <   0.001), whereas that of 
COPD and controls remained unchanged (Fig. S5, available 
at http://www.jem.org/cgi/content/full/jem.20070956/DC1). 
However, ethidium bromide also decreased BrdU incorpor-
ation of BSM cells from the three groups of subjects (  Fig. 6 D  ). 
In a second alternative approach, we stimulated mitochon-
drial biogenesis using cyclic GMP for 6 d, as previously de-
scribed (  16  ). The amount of mitochondria increased in such 
stimulated BSM cells from both COPD and controls (  Fig. 7  ; 
P = 0.02 for both). Because the amount of mitochondria 
was already up-regulated in BSM cells from asthmatics, cy-
clic GMP failed to additionally increase the porin content 
(P = 0.2). Cyclic GMP signifi  cantly decreased the doubling 
time (P = 0.01), and increased the BrdU incorporation 
(P = 0.02) and the proliferation of BSM cells from COPD 
patients (P = 0.01) (  Fig. 6, C and D,   and Fig. S5). Similarly, 
cyclic GMP also decreased the doubling time (P   <   0.001) 
and increased the BrdU incorporation (P   <   0.001) and the 
proliferation of BSM cells from controls (P   <   0.001;   Fig. 6, 
C and D,   and Fig. S5). However, cyclic GMP had no eff  ect 
in asthmatic BSM cell growth and proliferation. Finally, in 
a last approach, we analyzed the eff  ect of altering calcium 
homeostasis on the proliferation of BSM cells. D600, which 
blocks calcium infl  ux (  Fig. 4 E  ) and the resulting increase in 
mitochondrial biogenesis and content only in asthmatic BSM 
cells (  Fig. 5  ), also signifi  cantly inhibited the increased BrdU 
oxidative phosphorylations, whereas that of COPD and con-
trol subjects mainly uses mitochondrial-independent anaero-
bic glycolysis. 
  Increased mitochondrial mass explains increased asthmatic 
BSM cell proliferation 
  To determine whether the increased mitochondrial biogen-
esis found in asthmatic BSM cells is a cause or a consequence 
of the asthmatic BSM cell increased proliferation, three alter-
native approaches were used. First, mitochondria-defi  cient 
BSM cells were generated using culture with ethidium bro-
mide, as previously described (  10, 15  ). After 16 d of culture, 
all of the asthmatic BSM cells died, whereas those from both 
COPD patients and controls were still alive up to 30 d in the 
ethidium bromide medium (unpublished data). 6 d of incubation 
with ethidium bromide signifi  cantly decreased the amount of 
    Figure 6.     Asthmatic BSM cell proliferation is mitochondria depen-
dent.   BSM cell proliferation curves were obtained using either glucose (A) 
or galactose (B) in the culture medium. The doubling times of cell growth 
(C) were obtained from the proliferation curves. (D) BrdU incorporations 
were measured. BSM cells were cultured in various experimental condi-
tions, i.e., glucose, galactose, glucose + ethidium bromide (Et Br), or glu-
cose + cyclic GMP (cGMP). BSM cells were obtained from asthmatic (black 
symbols and columns;   n   = 4), COPD (gray symbols and columns;   n   =  4), 
and control subjects (white symbols and columns;   n   = 4). Data are the 
mean   ±   the SEM. *, P   <   0.05 between populations within an experimental 
condition using ANOVA with the use of Bonferroni  ’  s test.   †  , P   <   0.05 be-
tween experimental conditions versus glucose within a population using 
paired Student’s   t   tests.   
    Figure 7.     Effect of ethidium bromide and cyclic GMP on the porin 
content.   Mitochondrial mass was assessed by the porin content using 
Western blot. BSM cells were obtained from asthmatic (black columns; 
  n   = 4), COPD (gray columns;   n   = 4), and control subjects (white columns; 
  n   = 4) and were cultured in the absence (-) or presence (+) of ethidium 
bromide (Et Br) or cyclic GMP (cGMP) for 6 d before the experiments. Data 
are the mean   ±   the SEM. *, P   <   0.05 between populations within an ex-
perimental condition using ANOVA with the use of Bonferroni  ’  s test.   †  , 
P   <   0.05 between experimental conditions versus glucose within a popu-
lation using paired Student’s   t   tests.   JEM VOL. 204, December 24, 2007 
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quantitative RT-PCR and Western blot to assess mitochon-
drial respiratory chain content, as mitochondrial overall con-
tent and respiratory chain content are not always linked (  19  ). 
  The increased number of mitochondria was limited to 
asthmatic BSM cells compared with endothelial and epithe-
lial cells from asthmatic, COPD, or control subjects. However, 
two characteristics of such asthmatic populations deserve fur-
ther comment. First, it is unlikely that asthma treatments in-
terfered with the observed changes because, on the one hand, 
9/17 COPD patients took treatments similar to that of asth-
matics, and, on the other hand, no diff  erence has been found 
between controls and COPD. Second, the younger mean age 
of the asthmatic population is unlikely to contribute to this in-
crease in mitochondrial content because (a) this increase per-
sisted when comparing asthmatics to a subgroup of nonsmoking 
controls whose mean age was similar, and (b) in skeletal muscle, 
if not any other muscle, age does not infl  uence mitochondrial 
content (  20  ). To the best of our knowledge, this is the fi  rst de-
scription of such mitochondrial characteristics in any type of 
smooth muscle cells with potential pathophysiological impli-
cations. It has been previously reported that in a variety of 
diff  erentiated tissues, a mitochondrial dysfunction increases 
mitochondrial biogenesis, suggesting a cellular compensatory 
mechanism (  21  ). However, there was no mitochondrial dys-
function in our study because the respiration of asthmatic BSM 
mitochondria was effi   ciently coupled. Similarly, artifi  cial activa-
tion of mitochondrial biogenesis of mouse neonatal cardiac my-
ocytes largely induced a coupled respiration (  22  ). 
  Mitochondrial biogenesis is controlled by many factors. 
PGC-1      is a well-known master activator of mitochondrial 
biogenesis through the production of both NRF-1 and mtTFA 
in various cell types, including myoblast (  23  ), fi  broblast, or adi-
pocytes (  24  ). In this study, we demonstrated that such a cascade 
is activated in asthmatic BSM cells, as shown by the concomi-
tant up-regulation of PGC-1     , NRF-1, and mtTFA. More-
over, cyclic GMP has been shown to activate PGC-1      and 
mitochondrial biogenesis in various cell lines, including U937, 
L6, and PC12 (  16, 25  ). We have observed that cyclic GMP 
induces mitochondrial biogenesis in both control and COPD 
BSM cells, but not in asthmatic BSM cells. These fi  ndings sug-
gest that mitochondrial biogenesis in asthmatic BSM cells may 
already be up-regulated. In this connection, cyclic GMP also 
improved cell proliferation of control and COPD BSM cells, 
but not those of asthmatics. It could be argued that cyclic GMP 
regulates many diff  erent genes in smooth muscle, such as vas-
cular smooth muscle (  26  ). However, cyclic GMP has been 
shown to inhibit, rather than enhance, the proliferation of vas-
cular smooth muscle cells, as well as that of mesangial cells and 
various fi  broblasts (  26  ). In addition, direct improvement of 
mitochondrial biogenesis by transgenic overexpression of 
PGC-1      activates skeletal muscle atrophy (  27  ) and cardiac 
muscle dysfunction (  22  ). Conversely, cyclic GMP increases the 
proliferation of endothelial cells, but the role of mitochondria 
in this phenomenon has not been investigated so far (  28  ). 
  PGC-1      activation can be calcium-dependent (  29  ). In this 
study, we found that CaMK-IV was more phosphorylated in 
incorporation in BSM cells from asthmatics, thus confi  rming 
that this enhanced cellular calcium infl  ux represents the ini-
tial priming event (  Fig. 8  ).  
    DISCUSSION   
  This study indicates that whereas both asthma and COPD 
are characterized by BSM remodeling, a specifi  c mitochon-
dria-dependent pathway is required for BSM proliferation 
only in asthma. This pathway is initiated by an altered cal-
cium homeostasis, upon the activation of asthmatic BSM cells 
(Fig. S6, available at http://www.jem.org/cgi/content/full/
jem.20070956/DC1). Proliferation of BSM in both health and 
COPD is, at the very least, less mitochondria dependent. Thus, 
these results suggest that mitochondria may represent a specifi  c 
new therapeutic target in airway remodeling in asthma. 
  In this study, we paid special attention when comparing 
data from severe asthmatics to that of COPD patients because 
both diseases have been shown to present smooth muscle re-
modeling (  2, 3, 17  ). Using a variety of diff  erent experimental 
approaches, we provide evidence that asthmatic BSM express 
a higher number of active mitochondria and a clear aspect of 
intense mitochondrial biogenesis. In our study, we assessed 
mitochondrial mass using various parameters, including the 
number of mitochondria by electron microscopy both ex vivo 
and in vitro, the mitochondrial network by confocal micros-
copy, and the porin content by Western blot. All of these 
methods provided consistent results. We also found signifi  cant 
correlations between in vitro BSM porin content, which is a 
relevant quantitative estimate of mitochondrial mass, and both 
the duration of the disease and the FEV  1  /FVC ratio within the 
asthmatic population. These correlations further support our 
hypothesis because, on the one hand, the longer the duration 
of the disease that is known to favor airway remodeling (  18  ), 
the higher the mitochondrial mass, and on the other hand, the 
lower the FEV  1  /FVC ratio, which also refl  ects airway remod-
eling, the higher the mitochondrial mass. Moreover, to obtain 
a comprehensive assessment of mitochondrial content, we ad-
ditionally measured the expression level of mtTFA by both 
    Figure 8.     Effect of methoxyverapamil (D600) on BSM cell prolif-
eration.   BSM cell proliferation was measured using BrdU incorporations. 
Cells were cultured in the absence (-) or presence (+) of 1   μ  M D600 for 
48 h. BSM cells were obtained from asthmatic (black columns;   n   = 4), COPD 
(gray columns;   n   = 4), and control subjects (white columns;   n   = 4). Data 
are the mean   ±   the SEM. *, P   <   0.05 between populations within an ex-
perimental condition using ANOVA with the use of Bonferroni  ’  s test.   †  , 
P   <   0.05 between the absence and the presence of D600 within a popula-
tion using paired Student’s   t   tests.   3180 SMOOTH MUSCLE MITOCHONDRIAL BIOGENESIS IN ASTHMA | Trian et al.
software (Soft Imaging System) at a magnifi  cation of 200  ×  . This smooth 
muscle area was normalized by the whole area of the corresponding tissues 
and presented as percentages of whole area. 
  Bronchial specimens were also embedded in epon for electron micros-
copy (Tecnai 12; Philips), as previously described (  39  ). 10 60-nm-thick 
ultrathin serial sections per specimen were cut and examined by a pathologist 
to locate whole nucleated BSM cells and endothelial and epithelial cells. The 
number of mitochondrial sections normalized by the whole-cell area and the 
density of mitochondria normalized by the cytoplasmic density were assessed 
manually in these 3 cell types from 10 to 25 measurements per section in a 
blinded fashion using ScanView and ImageJ (National Institutes of Health) 
softwares at a magnifi  cation of 6000  ×  . 
  Primary cultures of BSM cells were established from bronchial specimens, 
as previously described (  37, 38, 40  ). All experiments were performed on phe-
notypically confi  rmed smooth muscle cells between passages 2 and 4. Cells 
were seeded on glass coverslips for confocal microscopy and microspectrofl  u-
orimetry, on culture fl  asks for electron microscopy and protein extraction, or 
on culture plates for RNA extraction. We used cells transfected with the plas-
mid mitochondrion-targeted GFP (mito-GFP) (  14  ) to obtain confocal images 
of the mitochondrial network. Such images were acquired with FluoView laser 
scanning microscope (Nikon) and reconstituted in three-dimensional images 
using Imaris Software (Bitplane) (  38  ). Immunoblotting was performed on cell 
protein extracts (  38, 40  ) using primary antibodies directed against porin, 
mtTFA, NRF-1, and PGC-1     . After reverse transcription, real-time quanti-
tative PCR was performed on a Rotor-Gene 2000 (Corbett Research) 
(  37, 38, 40  ), using appropriate primers designed to target mtTFA, NRF-1, or 
PGC-1     . Endogenous cell oxygen consumption, as well as coupling degree, 
were assessed in a thermostatically controlled chamber equipped with a Clark 
oxygen electrode (Oxygraph System; Hansatech), as previously described (  14  ). 
Cell calcium was assessed by microspectrofl  uorimetry using Indo-1 probe, as 
previously described (  40, 41  ). Cell proliferation was evaluated using both 
BrdU incorporation and cell counting. Cell apoptosis was fi  nally studied using 
FITC  –  Annexin V and fl  ow cytometry. A complete description of all methods 
is available in the Supplemental materials and methods. 
  Statistical analysis.     The statistical analysis was performed with NCSS 2001 
software. Comparison between the three groups was performed by means 
of ANOVA, with the use of Bonferroni  ’  s test for multiple comparisons or 
paired Student’s   t   tests. Values are presented as the mean   ±   the SEM. A 
Pearson correlation matrix was built between in vitro and in vivo measure-
ments. A P value   <  0.05 was considered statistically signifi  cant. 
  Online supplemental material.     Fig. S1 provides ultrastructural character-
istics of mitochondria from pellets of BSM cells. Fig. S2 demonstrates cou-
pled endogenous BSM cell respiration. Fig. S3 provides BSM cell intracellular 
calcium responses to histamine. Fig. S4 shows spontaneous BSM cell apop-
tosis. Fig. S5 shows the eff  ect of ethidium bromide and cyclic GMP on BSM 
cell proliferation. Fig. S6 illustrates the mechanisms of BSM proliferation in 
asthma. The online version of this article is available at http://www.jem
.org/cgi/content/full/jem.20070956/DC1. 
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